Analytic and Translational Genetics Unit, MGH, Boston, MA, USA.
Broad Institute, Cambridge, MA, USA.
Eur J Hum Genet. 2019 May;27(5):824-828. doi: 10.1038/s41431-019-0346-0. Epub 2019 Feb 4.
Along with traditional effects of aging and carcinogen exposure-inherited DNA variation has substantial contribution to cancer risk. Extraordinary progress made in analysis of common variation with GWAS methodology does not provide sufficient resolution to understand rare variation. To fulfill missing classification for rare germline variation we assembled dataset of whole exome sequences from>2000 patients (selected cases tested negative for candidate genes and unselected cases) with different types of cancers (breast cancer, colon cancer, and cutaneous and ocular melanomas) matched to more than 7000 non-cancer controls and analyzed germline variation in known cancer predisposing genes to identify common properties of disease-associated DNA variation and aid the future searches for new cancer susceptibility genes. Cancer predisposing genes were divided into non-overlapping classes according to the mode of inheritance of the related cancer syndrome or known tumor suppressor activity. Out of all classes only genes linked to dominant syndromes presented significant rare germline variants enrichment in cases. Separate analysis of protein-truncating and missense variation in this list of genes confirmed significant prevalence of protein-truncating variants in cases only in loss-of-function tolerant genes (pLI < 0.1), while ultra-rare missense variants were significantly overrepresented in cases only in constrained genes (pLI > 0.9). In addition to findings in genetically enriched cases, we observed significant burden of rare variation in unselected cases, suggesting substantial role of inherited variation even in relatively late cancer manifestation. Taken together, our findings provide reference for distribution and types of DNA variation underlying inherited predisposition to some common cancer types.
除了传统的衰老和致癌物暴露的影响外,遗传 DNA 变异对癌症风险也有很大的影响。GWAS 方法在分析常见变异方面取得了非凡的进展,但仍不足以解析稀有变异。为了更好地了解罕见种系变异,我们收集了 2000 多名患有不同类型癌症(乳腺癌、结肠癌、皮肤和眼黑色素瘤)患者的外显子组序列数据集(选择候选基因检测为阴性的病例和未选择的病例),这些患者与超过 7000 名非癌症对照相匹配,并分析了已知的癌症易感基因中的种系变异,以确定疾病相关 DNA 变异的共同特征,并有助于未来寻找新的癌症易感性基因。根据相关癌症综合征的遗传模式或已知的肿瘤抑制活性,将癌症易感基因分为非重叠类。在所有类别中,只有与显性综合征相关的基因在病例中表现出显著的稀有种系变异富集。对该基因列表中的蛋白质截断和错义变异进行单独分析,仅在功能丧失耐受基因(pLI<0.1)中确认了病例中蛋白质截断变异的显著流行,而在约束基因(pLI>0.9)中仅在病例中观察到超稀有错义变异的显著过表达。除了在遗传富集病例中发现的结果外,我们还观察到未选择病例中罕见变异的显著负担,这表明即使在癌症相对晚期,遗传变异也起着重要作用。总之,我们的研究结果为某些常见癌症类型的遗传易感性所涉及的 DNA 变异的分布和类型提供了参考。